MA51672A - Composés destinés au traitement des troubles kinases-dépendants - Google Patents

Composés destinés au traitement des troubles kinases-dépendants

Info

Publication number
MA51672A
MA51672A MA051672A MA51672A MA51672A MA 51672 A MA51672 A MA 51672A MA 051672 A MA051672 A MA 051672A MA 51672 A MA51672 A MA 51672A MA 51672 A MA51672 A MA 51672A
Authority
MA
Morocco
Prior art keywords
kinasis
treatment
compounds intended
dependent disorders
disorders
Prior art date
Application number
MA051672A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA51672A publication Critical patent/MA51672A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051672A 2018-01-26 2019-01-25 Composés destinés au traitement des troubles kinases-dépendants MA51672A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622626P 2018-01-26 2018-01-26
US201862622629P 2018-01-26 2018-01-26

Publications (1)

Publication Number Publication Date
MA51672A true MA51672A (fr) 2020-12-02

Family

ID=65409542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051672A MA51672A (fr) 2018-01-26 2019-01-25 Composés destinés au traitement des troubles kinases-dépendants

Country Status (18)

Country Link
US (2) US11708367B2 (fr)
EP (1) EP3743068A1 (fr)
JP (2) JP7307733B2 (fr)
KR (1) KR20200124678A (fr)
CN (1) CN112312909A (fr)
AU (1) AU2019212719A1 (fr)
BR (1) BR112020015199A2 (fr)
CA (1) CA3088127A1 (fr)
CL (1) CL2020001930A1 (fr)
CO (1) CO2020010467A2 (fr)
CR (1) CR20200355A (fr)
IL (2) IL302626A (fr)
MA (1) MA51672A (fr)
MX (2) MX2020007759A (fr)
PE (1) PE20210044A1 (fr)
PH (1) PH12020551059A1 (fr)
SG (1) SG11202006945PA (fr)
WO (1) WO2019148036A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015201A2 (pt) * 2018-01-26 2020-12-29 Exelixis, Inc. Compostos para tratamento contra distúrbios dependentes de quinase
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
MX2020007759A (es) * 2018-01-26 2020-09-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
CN115244041A (zh) * 2020-03-10 2022-10-25 南京明德新药研发有限公司 乙烯基取代吡啶类化合物
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP2295415A1 (fr) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Derives de quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR20060052867A (ko) 2003-07-23 2006-05-19 엑셀리시스, 인코포레이티드 약제로서의 아제핀 유도체
AU2004275842B2 (en) 2003-09-26 2010-09-02 Exelixis Inc. c-MET modulators and methods of use
EP1871417B1 (fr) 2005-04-15 2013-09-11 Precision Biologics, Inc. Anticorps monoclonaux recombinés et antigènes correspondants contre les cancers du colon et du pancréas
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
JP5734193B2 (ja) 2008-10-14 2015-06-17 クイ ニング 化合物及び使用方法
EP2214019A1 (fr) 2009-01-28 2010-08-04 Externautics S.p.A. Marqueurs de tumeurs et leurs utilisations
EP2213686A1 (fr) 2009-01-28 2010-08-04 Externautics S.p.A. Marqueurs de tumeur et procédés d'utilisation correspondants
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
WO2011051280A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
US20120322075A1 (en) 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
EP2494362B1 (fr) 2009-10-26 2016-06-08 Externautics S.p.A. Marqueurs de tumeur de la prostate et méthodes d'utilisation
WO2011051276A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation
EP2383578A1 (fr) 2010-04-30 2011-11-02 Externautics S.p.A. Marqueur de tumeur et procédés d'utilisation correspondants
US9242991B2 (en) * 2010-07-14 2016-01-26 Betta Pharmaceuticals Co., Ltd Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド ヒトモノクローナル抗pd−l1抗体および使用方法
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
EP3008086A2 (fr) 2013-06-14 2016-04-20 Externautics S.p.A. Marqueur de tumeur, anticorps monoclonaux et procédés pour les utiliser
US20150202291A1 (en) 2013-11-05 2015-07-23 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
AU2015249232B2 (en) 2014-04-25 2020-06-25 Exelixis, Inc. Method of treating lung adenocarcinoma
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品(宁波)有限公司 一种防老化阳光面料
CN107235896B (zh) 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
WO2019125798A1 (fr) 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Composés de carbamate et d'urée utilisés comme inhibiteurs de multikinases
MX2020007759A (es) * 2018-01-26 2020-09-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.

Also Published As

Publication number Publication date
PH12020551059A1 (en) 2021-05-31
SG11202006945PA (en) 2020-08-28
EP3743068A1 (fr) 2020-12-02
PE20210044A1 (es) 2021-01-08
JP2023082042A (ja) 2023-06-13
JP7307733B2 (ja) 2023-07-12
MX2022014351A (es) 2022-12-13
AU2019212719A1 (en) 2020-08-20
US20210040099A1 (en) 2021-02-11
CL2020001930A1 (es) 2020-12-11
US11708367B2 (en) 2023-07-25
WO2019148036A1 (fr) 2019-08-01
CA3088127A1 (fr) 2019-08-01
IL302626A (en) 2023-07-01
JP2021511359A (ja) 2021-05-06
CO2020010467A2 (es) 2020-10-30
US20230374024A1 (en) 2023-11-23
CR20200355A (es) 2021-02-22
BR112020015199A2 (pt) 2021-05-04
IL276028A (en) 2020-08-31
CN112312909A (zh) 2021-02-02
KR20200124678A (ko) 2020-11-03
MX2020007759A (es) 2020-09-24

Similar Documents

Publication Publication Date Title
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA53172A (fr) Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA52778A (fr) Méthodes de traitement de troubles associés au récepteur s1p1
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA51046A (fr) Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA51738A (fr) Composés pour le traitement de la douleur
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
MA56114A (fr) Composés pour le traitement de troubles dépendant de la kinase
MA47212A (fr) Méthodes de traitement de troubles neurologiques
MA52761A (fr) Schéma posologique destiné au traitement de troubles liés à la pi3k
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA53664A (fr) Composés destinés au traitement de certaines leucémies
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs